Abingworth Llp Has Cut Dicerna (DRNA) Stake By $1.22 Million, Atlas Air Worldwide Holdings, Inc. (AAWW) Covered By 2 Bulls

June 19, 2017 - By Winifred Garcia

Among 4 analysts covering Atlas Air Worldwide Holdings (NASDAQ:AAWW), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Atlas Air Worldwide Holdings had 10 analyst reports since August 5, 2015 according to SRatingsIntel. Imperial Capital maintained the shares of AAWW in report on Wednesday, August 5 with “Outperform” rating. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, December 13. As per Friday, August 26, the company rating was initiated by Stifel Nicolaus. The rating was maintained by Imperial Capital on Friday, September 25 with “In-Line”. Cowen & Co maintained it with “Market Perform” rating and $55 target in Friday, May 6 report. The stock of Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW) has “Market Perform” rating given on Friday, November 4 by Cowen & Co. The stock of Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW) earned “Sector Perform” rating by RBC Capital Markets on Friday, May 6. The stock of Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW) earned “Outperform” rating by Imperial Capital on Thursday, November 17. The rating was maintained by RBC Capital Markets on Friday, November 6 with “Sector Perform”. Cowen & Co maintained Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW) rating on Friday, November 6. Cowen & Co has “Market Perform” rating and $50 target. See Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW) latest ratings:

Abingworth Llp decreased Dicerna (DRNA) stake by 64.28% reported in 2016Q4 SEC filing. Abingworth Llp sold 607,932 shares as Dicerna (DRNA)’s stock rose 12.37%. The Abingworth Llp holds 337,825 shares with $973,000 value, down from 945,757 last quarter. Dicerna now has $63.13 million valuation. The stock rose 2.90% or $0.09 reaching $3.02. About 39,011 shares traded. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has declined 5.22% since June 19, 2016 and is downtrending. It has underperformed by 21.92% the S&P500.

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals had 12 analyst reports since August 7, 2015 according to SRatingsIntel. Leerink Swann reinitiated the stock with “Mkt Perform” rating in Tuesday, January 31 report. The firm has “Outperform” rating given on Tuesday, September 8 by Cowen & Co. On Monday, August 10 the stock rating was maintained by Stifel Nicolaus with “Buy”. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus on Thursday, June 30. The firm earned “Buy” rating on Monday, December 12 by H.C. Wainwright. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has “Neutral” rating given on Thursday, June 30 by Chardan Capital Markets. As per Monday, August 15, the company rating was maintained by Chardan Capital Markets. The company was maintained on Tuesday, May 10 by Stifel Nicolaus. Stifel Nicolaus maintained Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) rating on Wednesday, November 11. Stifel Nicolaus has “Buy” rating and $20 target.

Investors sentiment increased to 1.09 in 2016 Q4. Its up 0.53, from 0.56 in 2016Q3. It is positive, as 10 investors sold DRNA shares while 13 reduced holdings. 10 funds opened positions while 15 raised stakes. 10.74 million shares or 7.45% less from 11.61 million shares in 2016Q3 were reported. Ra Capital Mngmt Lc reported 1.02% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Qs Invsts Lc owns 1,071 shares for 0% of their portfolio. Wells Fargo And Company Mn accumulated 140 shares. 2,257 were accumulated by Blackrock. Eventide Asset Mgmt Lc accumulated 377,000 shares or 0.07% of the stock. Blackrock Investment Mngmt Limited Company accumulated 2,889 shares or 0% of the stock. Bank Of Montreal Can holds 27,609 shares. Parametric Assocs Lc holds 0% or 11,796 shares in its portfolio. California Pub Employees Retirement holds 0% or 41,000 shares in its portfolio. Morgan Stanley reported 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Paloma Ptnrs Mgmt holds 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 106,869 shares. Citigroup Incorporated reported 1,097 shares or 0% of all its holdings. Barclays Public Ltd Com reported 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). 683 Capital Ltd Liability Corp reported 0.15% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Prelude Lc has invested 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: